{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:52:28Z","timestamp":1793411548372,"version":"4.5.0"},"reference-count":31,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2023,10,7]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Less than 1% of all clinical trials are conducted in Africa. In 2019, only six of 26 oncology clinical trials conducted in Africa were conducted in countries with subjects of African ancestry. There are multiple barriers that hinder the conduct of cancer clinical trials in Africa. Time to trial activation (TTA) is the administrative and regulatory process required before a study can be activated\u2014an important metric and often a major barrier for site selection. In Kenya, TTA involves review by Institutional Review Board (IRB), Pharmacy and Poisons Board, National Commission for Science, Technology and Innovation and Ministry of Health, all in a sequential fashion. We performed a prospective review of TTA for all clinical trials initiated and began enrolment at the Aga Khan University-Clinical Research Unit between June 2020 and November 2022. TTA was defined as total time from submission of study documents (to regulatory bodies) to site activation by the sponsor. A total of 12 studies were submitted for regulatory review. Eleven (nine industry sponsored and two investigator initiated) were approved for activation. Three were COVID-19-related studies and eight were non-COVID-19-related studies. Mean TTA for COVID-related studies was 80 days (range 40\u2013120). Mean TTA for non-COVID-related studies was 259 days (range 190\u2013399). This TTA difference was statistically significant (p=0.02). TTA remains a significant barrier to the efficient regulatory approval of and subsequent conduct of clinical trials in Africa. COVID-19 pandemic revealed that parallel processing and expedited review of clinical trials allows efficient TTA without compromising human subject safety or data integrity. These lessons need to be applied to all clinical trials in order for African sites to become competitive and contribute data from African patients to global knowledge.<\/jats:p>","DOI":"10.1136\/bmjgh-2023-013727","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T13:35:48Z","timestamp":1706103348000},"page":"e013727","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Regulatory approval of clinical trials: is it time to reinvent the wheel?"],"prefix":"10.1136","volume":"9","author":[{"given":"Mansoor","family":"Saleh","sequence":"first","affiliation":[{"name":"Hematology and Oncology, The Aga Khan University Hospital, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0798-0745","authenticated-orcid":false,"given":"Karishma","family":"Sharma","sequence":"additional","affiliation":[{"name":"The Aga Khan University Hospital, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisleen","family":"Shamshudin","sequence":"additional","affiliation":[{"name":"The Aga Khan University Hospital, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Innocent","family":"Obayo","sequence":"additional","affiliation":[{"name":"The Aga Khan University Hospital, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Gondi","sequence":"additional","affiliation":[{"name":"The Aga Khan University Hospital, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noureen","family":"Karimi","sequence":"additional","affiliation":[{"name":"The Aga Khan University Hospital, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"2025072914321211000_9.1.e013727.1","unstructured":"Strengthening clinical research capacity in low-and middle-income countries Workshop report, Available: https:\/\/acmedsci.ac.uk\/file-download\/22417547"},{"key":"2025072914321211000_9.1.e013727.2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/qjmed\/hcab010","article-title":"Why is there a paucity of clinical trials in Africa?","volume":"114","author":"Taylor-Robinson","year":"2021","journal-title":"QJM"},{"key":"2025072914321211000_9.1.e013727.3","unstructured":"Clinical Trials Arena . The dynamics of clinical research in Africa: 2016-21, Available: https:\/\/www.clinicaltrialsarena.com\/comment\/clinical-research-africa-2016-21\/"},{"key":"2025072914321211000_9.1.e013727.4","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/GO.21.00096","article-title":"Cancer clinical trials in Africa-an untapped opportunity: recommendations from AORTIC 2019 conference special interest group in clinical trials","volume":"7","author":"Ibraheem","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"2025072914321211000_9.1.e013727.5","unstructured":"African Countries With The Highest Number of Doctors . Theratio of doctors To,4.3 million doctors by 2035. n.d. Available: https:\/\/blog.mustardinsights.com\/in-africa\/african-countries-with-the-highest-number-of-doctors-ednQo#:~:text="},{"key":"2025072914321211000_9.1.e013727.6","unstructured":"Sub-Saharan Africa, Data Physicians (per 1,000 people), Available: https:\/\/data.worldbank.org\/indicator\/SH.MED.PHYS.ZS?locations=ZG"},{"key":"2025072914321211000_9.1.e013727.7","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/GO.21.00096","article-title":"Cancer clinical trials in Africa-an untapped opportunity: recommendations from AORTIC 2019 conference special interest group in clinical trials","volume":"7","author":"Ibraheem","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"2025072914321211000_9.1.e013727.8","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-020-04620-8","article-title":"Conducting clinical trials in sub-Saharan Africa: challenges and lessons learned from the Malawi Cryptosporidium study","volume":"21","author":"Toto","year":"2020","journal-title":"Trials"},{"key":"2025072914321211000_9.1.e013727.9","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JGO.19.00204","article-title":"Operational strategies for clinical trials in Africa","volume":"6","author":"Graef","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"2025072914321211000_9.1.e013727.10","doi-asserted-by":"crossref","first-page":"107092","DOI":"10.1016\/j.cct.2023.107092","article-title":"Diversity, equity, and inclusion in clinical trials: A practical guide from the perspective of a trial sponsor","volume":"126","author":"Versavel","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"2025072914321211000_9.1.e013727.11","unstructured":"Disparities H , Institute on Minority Health N . National Institutes of health minority health and health disparities strategic plan 2021 to 2025: taking the next steps. 2021. Available: https:\/\/www.nimhd.nih.gov\/docs\/nimhd-strategic-plan-2021-2025.pdf"},{"key":"2025072914321211000_9.1.e013727.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.10.040"},{"key":"2025072914321211000_9.1.e013727.13","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-53501-6.00025-1"},{"key":"2025072914321211000_9.1.e013727.14","doi-asserted-by":"crossref","DOI":"10.1080\/16549716.2020.1846904","article-title":"Strengthening research capacity in Lmics to address the global NCD burden","volume":"13","author":"Malekzadeh","year":"2020","journal-title":"Glob Health Action"},{"key":"2025072914321211000_9.1.e013727.15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2019-001747","article-title":"Developing a framework of core Competencies in implementation research for low\/middle-income countries","volume":"4","author":"Alonge","year":"2019","journal-title":"BMJ Glob Health"},{"key":"2025072914321211000_9.1.e013727.16","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2022.1411","article-title":"What does it take to conduct clinical trials in African countries? insights from Morocco","volume":"16","author":"Benhima","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"2025072914321211000_9.1.e013727.17","unstructured":"Discussion paper: developing a clinical trials infrastructure. 2012. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK114674"},{"key":"2025072914321211000_9.1.e013727.18","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.drudis.2020.08.001","article-title":"Global clinical trial mobilization for COVID-19: higher, faster, stronger","volume":"25","author":"Beall","year":"2020","journal-title":"Drug Discov Today"},{"key":"2025072914321211000_9.1.e013727.19","unstructured":"WHO . COVID-19 Public Health Emergency of International Concern (PHEIC) Global research and innovation forum. World Health Organization, 2020. Available: https:\/\/www.who.int\/publications\/m\/item\/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum"},{"key":"2025072914321211000_9.1.e013727.20","unstructured":"Regional Office for Africa . African Vaccine Regulatory Forum (AVAREF) - Joint Review Process, Available: https:\/\/www.afro.who.int\/health-topics\/immunization\/avaref\/joint-review-process"},{"key":"2025072914321211000_9.1.e013727.21","unstructured":"Regional Office for Africa . African regulatory agencies, ethics committees to expedite COVID-19 clinical trial reviews, Available: https:\/\/www.afro.who.int\/news\/african-regulatory-agencies-ethics-committees-expedite-covid-19-clinical-trial-reviews"},{"key":"2025072914321211000_9.1.e013727.22","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00243-1"},{"key":"2025072914321211000_9.1.e013727.23","unstructured":"Grenfell A , Rickwood S . Clinical development will meet Africa\u2019s unique health needs | world economic forum. 2022. Available: https:\/\/www.weforum.org\/agenda\/2022\/05\/how-clinical-development-can-meet-africas-unique-health-needs\/"},{"key":"2025072914321211000_9.1.e013727.24","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1200\/OP.19.00325","article-title":"Improving the time to activation of new clinical trials at a national cancer Institute-designated comprehensive cancer center","volume":"16","author":"Williams","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2025072914321211000_9.1.e013727.25","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JGO.19.00189","article-title":"Landscape of oncology clinical trials in Africa","volume":"6","author":"Odedina","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"2025072914321211000_9.1.e013727.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12939-018-0748-6","article-title":"Barriers for conducting clinical trials in developing Countries- a systematic review","volume":"17","author":"Alemayehu","year":"2018","journal-title":"Int J Equity Health"},{"key":"2025072914321211000_9.1.e013727.27","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_351333"},{"key":"2025072914321211000_9.1.e013727.28","unstructured":"The Ethical Implications of Clinical Trials in Low- and Middle-Income Countries, Available: https:\/\/www.americanbar.org\/groups\/crsj\/publications\/human_rights_magazine_home\/the-truth-about-science\/the-ethical-implications-of-clinical-trials\/"},{"key":"2025072914321211000_9.1.e013727.29","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1031121"},{"key":"2025072914321211000_9.1.e013727.30","doi-asserted-by":"crossref","DOI":"10.29392\/joghr.3.e2019082","article-title":"Clinical research in Africa and Middle East: roadmap for reform and Harmonisation of the regulatory framework and sustainable capacity development","volume":"3","author":"Zannad","year":"2019","journal-title":"Journal of Global Health Reports"},{"key":"2025072914321211000_9.1.e013727.31","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.742200","article-title":"Evaluation of the review models and approval Timelines of countries participating in the Southern African development community: alignment and strategies for moving forward","volume":"8","author":"Sithole","year":"2021","journal-title":"Front Med (Lausanne)"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2023-013727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T21:32:23Z","timestamp":1753824743000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2023-013727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,24]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/bmjgh-2023-013727"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2023-013727","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}